Emerging targets in treating pain

David S. Chang, Rahul Raghavan, Sandy Christiansen, Steven P. Cohen

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Purpose of review To provide an overview on drug targets and emerging pharmacological treatment options for chronic pain. Recent findings Chronic pain poses an enormous socioeconomic burden for the more than 30% of people who suffer from it, costing over $600 billion per year in the USA. In recent years, there has been a surge in preclinical and clinical research endeavors to try to stem this epidemic. Preclinical studies have identified a wide array of potential targets, with some of the most promising translational research being performed on novel opioid receptors, cannabinoid receptors, selective ion channel blockers, cytokine inhibitors, nerve growth factor inhibitors, N-methyl-d-aspartate receptor antagonists, glial cell inhibitors, and bisphosphonates. Summary There are many obstacles for the development of effective medications to treat chronic pain, including the inherent challenges in identifying pathophysiological mechanisms, the overlap and multiplicity of pain pathways, and off-target adverse effects stemming from the ubiquity of drug target receptor sites and the lack of highly selective receptor ligands. Despite these barriers, the number and diversity of potential therapies have continued to grow, to include disease-modifying and individualized drug treatments.

Original languageEnglish (US)
Pages (from-to)379-397
Number of pages19
JournalCurrent Opinion in Anaesthesiology
Volume28
Issue number4
DOIs
StatePublished - Jan 1 2015
Externally publishedYes

Fingerprint

Chronic Pain
Pain
Drug Receptors
Cannabinoid Receptors
Translational Medical Research
Diphosphonates
Opioid Receptors
Nerve Growth Factor
Ion Channels
Neuroglia
Pharmaceutical Preparations
Therapeutics
Pharmacology
Cytokines
Ligands
Research
aspartic acid receptor

Keywords

  • analgesia
  • chronic pain
  • drug discovery
  • neuropathic pain
  • nociceptive pain

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Emerging targets in treating pain. / Chang, David S.; Raghavan, Rahul; Christiansen, Sandy; Cohen, Steven P.

In: Current Opinion in Anaesthesiology, Vol. 28, No. 4, 01.01.2015, p. 379-397.

Research output: Contribution to journalReview article

Chang, David S. ; Raghavan, Rahul ; Christiansen, Sandy ; Cohen, Steven P. / Emerging targets in treating pain. In: Current Opinion in Anaesthesiology. 2015 ; Vol. 28, No. 4. pp. 379-397.
@article{b295f5b960004141aa0218567a1cbfe7,
title = "Emerging targets in treating pain",
abstract = "Purpose of review To provide an overview on drug targets and emerging pharmacological treatment options for chronic pain. Recent findings Chronic pain poses an enormous socioeconomic burden for the more than 30{\%} of people who suffer from it, costing over $600 billion per year in the USA. In recent years, there has been a surge in preclinical and clinical research endeavors to try to stem this epidemic. Preclinical studies have identified a wide array of potential targets, with some of the most promising translational research being performed on novel opioid receptors, cannabinoid receptors, selective ion channel blockers, cytokine inhibitors, nerve growth factor inhibitors, N-methyl-d-aspartate receptor antagonists, glial cell inhibitors, and bisphosphonates. Summary There are many obstacles for the development of effective medications to treat chronic pain, including the inherent challenges in identifying pathophysiological mechanisms, the overlap and multiplicity of pain pathways, and off-target adverse effects stemming from the ubiquity of drug target receptor sites and the lack of highly selective receptor ligands. Despite these barriers, the number and diversity of potential therapies have continued to grow, to include disease-modifying and individualized drug treatments.",
keywords = "analgesia, chronic pain, drug discovery, neuropathic pain, nociceptive pain",
author = "Chang, {David S.} and Rahul Raghavan and Sandy Christiansen and Cohen, {Steven P.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1097/ACO.0000000000000216",
language = "English (US)",
volume = "28",
pages = "379--397",
journal = "Current Opinion in Anaesthesiology",
issn = "0952-7907",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Emerging targets in treating pain

AU - Chang, David S.

AU - Raghavan, Rahul

AU - Christiansen, Sandy

AU - Cohen, Steven P.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose of review To provide an overview on drug targets and emerging pharmacological treatment options for chronic pain. Recent findings Chronic pain poses an enormous socioeconomic burden for the more than 30% of people who suffer from it, costing over $600 billion per year in the USA. In recent years, there has been a surge in preclinical and clinical research endeavors to try to stem this epidemic. Preclinical studies have identified a wide array of potential targets, with some of the most promising translational research being performed on novel opioid receptors, cannabinoid receptors, selective ion channel blockers, cytokine inhibitors, nerve growth factor inhibitors, N-methyl-d-aspartate receptor antagonists, glial cell inhibitors, and bisphosphonates. Summary There are many obstacles for the development of effective medications to treat chronic pain, including the inherent challenges in identifying pathophysiological mechanisms, the overlap and multiplicity of pain pathways, and off-target adverse effects stemming from the ubiquity of drug target receptor sites and the lack of highly selective receptor ligands. Despite these barriers, the number and diversity of potential therapies have continued to grow, to include disease-modifying and individualized drug treatments.

AB - Purpose of review To provide an overview on drug targets and emerging pharmacological treatment options for chronic pain. Recent findings Chronic pain poses an enormous socioeconomic burden for the more than 30% of people who suffer from it, costing over $600 billion per year in the USA. In recent years, there has been a surge in preclinical and clinical research endeavors to try to stem this epidemic. Preclinical studies have identified a wide array of potential targets, with some of the most promising translational research being performed on novel opioid receptors, cannabinoid receptors, selective ion channel blockers, cytokine inhibitors, nerve growth factor inhibitors, N-methyl-d-aspartate receptor antagonists, glial cell inhibitors, and bisphosphonates. Summary There are many obstacles for the development of effective medications to treat chronic pain, including the inherent challenges in identifying pathophysiological mechanisms, the overlap and multiplicity of pain pathways, and off-target adverse effects stemming from the ubiquity of drug target receptor sites and the lack of highly selective receptor ligands. Despite these barriers, the number and diversity of potential therapies have continued to grow, to include disease-modifying and individualized drug treatments.

KW - analgesia

KW - chronic pain

KW - drug discovery

KW - neuropathic pain

KW - nociceptive pain

UR - http://www.scopus.com/inward/record.url?scp=84937938414&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937938414&partnerID=8YFLogxK

U2 - 10.1097/ACO.0000000000000216

DO - 10.1097/ACO.0000000000000216

M3 - Review article

VL - 28

SP - 379

EP - 397

JO - Current Opinion in Anaesthesiology

JF - Current Opinion in Anaesthesiology

SN - 0952-7907

IS - 4

ER -